Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Equity Ratio (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Equity Ratio data on record, last reported at 0.64 in Q4 2025.

  • For Q4 2025, Equity Ratio fell 9.01% year-over-year to 0.64; the TTM value through Dec 2025 reached 0.64, down 9.01%, while the annual FY2025 figure was 0.64, 9.01% down from the prior year.
  • Equity Ratio reached 0.64 in Q4 2025 per ACRS's latest filing, down from 0.68 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.85 in Q2 2022 and bottomed at 0.64 in Q4 2025.
  • Average Equity Ratio over 5 years is 0.76, with a median of 0.77 recorded in 2022.
  • Peak YoY movement for Equity Ratio: soared 47.69% in 2021, then fell 16.17% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.79 in 2021, then dropped by 1.19% to 0.78 in 2022, then increased by 2.58% to 0.8 in 2023, then decreased by 11.33% to 0.71 in 2024, then fell by 9.01% to 0.64 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.64 in Q4 2025, 0.68 in Q3 2025, and 0.7 in Q2 2025.